Successful treatment of pure red cell aplasia associated with systemic lupus erythematosus with oral danazol and steroid
A systemic lupus erythematosus patient with steroid-refractory pure red cell aplasia achieved remission with combined oral danazol and low-dose prednisolone therapy.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This paper describes a middle-aged Chinese patient with systemic lupus erythematosus (SLE) who developed pure red cell aplasia that was refractory to steroids and resulted in transfusion dependence. The authors treated the patient with oral danazol 200 mg twice daily in combination with low-dose prednisolone, reporting no further recurrence of anemia one month after starting therapy. The primary limitation is that this is a single-patient case report with a short follow-up and no comparator arm, so generalizability and long-term efficacy cannot be established. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Full text
2,986 characters
· extracted from
oa-doi-fallback
· 2 sections
· click to expand
Abstract
References
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (13)
- Efficacy of danazol in pure red cell aplasia via openalex
- doi:10.1159/000204509 via openalex
- W30538064 via openalex
- doi:10.1080/03009749950154293 via openalex
- doi:10.1177/096120339500400512 via openalex
- doi:10.3349/ymj.2002.43.2.274 via openalex
- doi:10.1182/blood.v63.2.277.277 via openalex
- doi:10.1182/blood.v63.2.277.bloodjournal632277 via openalex
- doi:10.1002/art.1780310518 via openalex
- doi:10.1093/rheumatology/39.10.1155 via openalex
- doi:10.1172/jci108729 via openalex
- doi:10.1111/j.1365-2141.1986.tb07495.x via openalex
- doi:10.1084/jem.147.6.1568 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T06:45:02.717393+00:00
- unpaywall
- last seen: 2026-06-18T06:36:33.011116+00:00